Anemia Medication Recall Could Affect Thousands Of Kidney-Disease PatientsThe Wall Street Journal: Drug Makers Recall Omontys Anemia Medication
The recall comes as a sharp blow to Affymax, a small biotechnology firm based in Palo Alto, Calif., that developed Omontys and has no other late-stage drugs in its pipeline. The move affects thousands of kidney-disease patients who have been receiving the drug, promoted as a cheaper and more convenient alternative to Amgen Inc.'s blockbuster Epogen, which holds a near-monopoly in treating anemia in that market (Walker, 2/24). This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.